U.S. Transportation Stock News

Agree Realty Corporation recently announced that its Board of Directors declared a 2.4% increase in the monthly cash dividend for common shareholders, raising the annualized payout to US$3.072 per share and declared a preferred dividend as well, both payable in September 2025. This dividend increase signals management’s confidence in the company’s financial health and ongoing commitment to delivering steady shareholder returns. We'll explore how boosting the common dividend payout may...

Monster Beverage Corporation reported its second quarter 2025 earnings results, with sales rising to US$2.11 billion and net income reaching US$488.79 million, both higher than the same period last year. The company showed growth in both revenue and profitability for the quarter, while announcing no share repurchases during the reported period. To assess the implications on Monster's investment narrative, we'll examine how robust earnings growth highlights the company's progress amid global...

Earlier this month, PROCEPT BioRobotics Corporation reported its second-quarter and first-half 2025 earnings, highlighting sales growth to US$79.18 million for the quarter and a narrowing net loss of US$19.58 million compared to the previous year. The company also raised its full-year 2025 revenue guidance to approximately US$325.5 million, reflecting confidence in sustained sales momentum and operational improvements. We'll now consider how this raised full-year revenue guidance could...

Millicom International Cellular S.A. recently reported its second quarter 2025 results, posting net income of US$676 million and basic earnings per share of US$4.05, despite a year-over-year decrease in sales to US$1.37 billion. This substantial rise in profitability, coupled with the approval of an interim dividend of US$2.50 per share, points to enhanced operational efficiency and strong shareholder returns even as revenues decreased. We’ll explore how robust earnings growth, even...

Rivian Automotive recently reported its second quarter 2025 results, with revenue reaching US$1.30 billion and net loss decreasing to US$1.12 billion compared to the prior year. The reduction in net loss alongside revenue growth highlights Rivian's ongoing efforts to improve operational efficiency and cost management as it scales production. We'll examine how Rivian's narrowing losses this quarter inform its prospects for cost control and operational progress within the investment...

On August 14, 2025, Lufax Holding announced that Mr. Weidong Li resigned as independent non-executive director and key committee member, with Ms. Wai Ping Tina Lee appointed as his replacement to bolster board diversity in line with updated governance standards. Ms. Lee brings over four decades of legal and banking experience to the board at a time when regulatory changes are driving greater female representation in corporate leadership. We'll examine how the focus on enhanced board...

Hudson Pacific Properties, Inc. recently reported its second quarter and first half 2025 results, showing declines in both revenue and sales alongside wider net losses compared to the prior year, and updated its GAAP non-cash revenue guidance for the full year to a range of US$5.5 million to US$10.5 million. The updated guidance and financial results highlight continued operational and market headwinds, with year-over-year losses expanding despite efforts to manage costs and reposition the...

Coherent Corp. reported financial results for the quarter and year ended June 30, 2025, with annual sales rising to US$5.81 billion and a return to full-year profitability, alongside new guidance for first quarter 2026 revenue between US$1.46 billion and US$1.60 billion. Apple announced the expansion of its multiyear supply agreement with Coherent, ensuring continued production of VCSELs that power advanced optoelectronic capabilities in Apple devices from Coherent’s Texas facility. We'll...

In recent weeks, Sarepta Therapeutics reported its second quarter 2025 results, disclosed a class action lawsuit related to ELEVIDYS safety concerns, and saw the European Medicines Agency recommend refusing marketing authorization for the gene therapy amid patient safety issues and regulatory scrutiny. The company is undergoing significant restructuring, including workforce reductions and a black box warning on ELEVIDYS, while also filing a US$77.05 million shelf registration tied to...

Axon Enterprise recently reported strong second quarter results, with revenue rising to US$668.54 million from US$503.24 million a year earlier, but net income declined compared to the prior year; it also raised its full-year 2025 revenue guidance to a new range of US$2.65 billion to US$2.73 billion. A key insight is that the company increased its annual revenue outlook following a period of significant sales growth, signaling sustained demand for its public safety solutions even as...

Navigator Holdings recently reported its second quarter 2025 results with sales of US$129.64 million and net income of US$21.45 million, alongside declaring a US$0.05 per share cash dividend and announcing completion of a US$50 million share buyback program for 4.92% of shares. This combination of ongoing shareholder returns and capital management initiatives occurred as the company showed both stability in earnings and an active approach to enhancing shareholder value. We'll explore how...

Protagonist Therapeutics recently reported its second quarter 2025 results, posting a net loss of US$34.77 million compared to US$30.62 million a year earlier, and announced a shelf registration statement allowing the potential sale of a range of securities in the future. The combination of a wider quarterly net loss and plans for possible future fundraising could signal a shift in the company's financial strategy and outlook. We’ll explore how the shelf registration announcement and...

National Health Investors, Inc. recently reported its second quarter 2025 results, showing increases in revenue and net income compared to the previous year, alongside an announced quarterly dividend of US$0.92 per share payable on October 31, 2025. Although sales and revenue advanced year over year, basic and diluted earnings per share from continuing operations slightly declined for the quarter, highlighting a shift in earnings allocation or cost structure. We'll take a closer look at how...

Rhythm Pharmaceuticals reported its second-quarter and first-half 2025 financial results, revealing revenue of US$48.5 million for the quarter, up from US$29.08 million a year earlier, and a significantly reduced net loss for the first six months compared to the same period last year. While the quarterly net loss expanded, the substantial narrowing of the six-month net loss highlights progress in operational efficiency and cost management amid revenue growth. We'll explore how the...

On August 6, 2025, Grand Canyon Education reported its second quarter and first half 2025 earnings, announcing net income of US$41.55 million for the quarter and US$113.16 million for the half year, along with higher basic and diluted earnings per share from continuing operations compared to the prior year. The company also raised its guidance for third and fourth quarter service revenue and diluted EPS, signaling stronger operational performance and confidence in its full-year outlook. We...

StoneX Group Inc. recently announced its third quarter and nine-month earnings, reporting revenue of US$34.83 billion and net income of US$63.4 million for the quarter ended June 30, 2025, both up from a year ago. An interesting insight is that while revenue saw a very large increase, diluted earnings per share for the quarter remained fairly stable year-over-year. We'll explore how StoneX Group's substantial revenue growth alongside steady quarterly profit margins plays into its broader...

MercadoLibre released its second quarter 2025 earnings, reporting US$6.79 billion in revenue and US$523 million in net income for the period ended June 30, 2025, compared to US$5.07 billion and US$531 million respectively a year earlier. Despite a small decrease in net income for the quarter, the company posted significant year-over-year revenue growth and a rise in net income for the first half of the year. We'll explore how strong revenue momentum amid mixed profitability impacts...

ReNew Energy Global Plc recently reported its first quarter FY26 results, recording INR41.18 billion in revenue and a net profit of INR5.13 billion, both showing significant year-over-year increases. The company's clean power capacity grew by 23% and ReNew surpassed analyst revenue estimates, while also reiterating guidance for continued capacity and operational expansion. We’ll explore how ReNew’s robust profit jump and clean energy capacity growth may shape the company’s longer-term...

National HealthCare Corporation recently reported its second quarter and six-month 2025 financial results, highlighting year-over-year revenue growth and confirming a quarterly dividend of US$0.64 per share for shareholders of record on September 30, 2025, payable on October 31, 2025. The combination of higher revenue and the continuation of regular dividend payments underscores the company’s commitment to returning value to shareholders despite a lower quarterly net income. We'll explore...

Earlier this month, Collegium Pharmaceutical reported a decrease in net income and earnings per share for the second quarter and first half of 2025 compared to the previous year, but raised its full-year net product revenue guidance and updated its buyback activity, including the repurchase of 692,281 shares for US$20.01 million during the last quarter. This combination of weaker earnings with increased revenue expectations and an ongoing share buyback program highlights a balancing act...

BeOne Medicines Ltd. recently reported second quarter 2025 earnings, showing revenue of US$1.32 billion and net income of US$94.32 million, marking a reversal from net losses in the previous year. The company also raised its full-year 2025 revenue guidance and now expects positive GAAP operating income, highlighting improved operational performance and momentum in its oncology business. We'll explore how BeOne's move to profitability and higher revenue guidance affect its investment...

On August 8, 2025, China Yuchai International Limited reported that for the half year ended June 30, 2025, sales reached CNY 13.81 billion and net income grew to CNY 365.79 million, both higher than the prior year. This marks a strong period of financial growth, with significant increases in both revenue and earnings per share compared to the same period last year. We'll examine how China Yuchai International's substantial revenue and net income growth may affect its longer-term investment...

AbCellera Biologics reported its second quarter and six-month earnings, showing quarterly revenue of US$17.08 million, more than doubling from a year ago, while six-month revenue reached US$21.32 million. Despite ongoing net losses, the strong revenue growth compared to the prior year signals business progress and could shift perceptions on the company’s operational momentum. We’ll examine how this recent revenue surge may affect the company’s outlook and the broader investment...

Travere Therapeutics recently announced its second quarter 2025 earnings, reporting revenue of US$114.45 million, compared to US$54.12 million for the same period last year, and a net loss of US$12.76 million versus US$70.41 million previously. This substantial year-over-year improvement in both revenue and net loss underscores the company's operational progress and strengthens its financial foundation. We'll explore how significant revenue gains and improved earnings performance influence...